@article{38c0cffebea74ed5ae19fcf9c79d46f2,
title = "Plitidepsin: a potential new treatment for relapsed/refractory multiple myeloma.",
keywords = "I DOSE-ESCALATION, EVERY 2 WEEKS, PHASE-II, 2ND-LINE THERAPY, HEMATOPOIETIC PROGENITORS, BIWEEKLY PLITIDEPSIN, LEUKEMIC-CELLS, VITRO TOXICITY, CANCER-CELLS, SOLID TUMORS",
author = "Michael Leisch and Alexander Egle and Richard Greil",
note = "all: Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology \& Rheumatology, Oncologic Center, Salzburg Cancer Research Institute – Laboratory of Immunological \& Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University, Salzburg, Austria, Cancer Cluster Salzburg, Austria",
year = "2019",
doi = "10.2217/fon-2018-0492",
language = "English",
volume = "15",
pages = "109--120",
journal = "FUTURE ONCOLOGY",
issn = "1479-6694",
number = "2",
}